Invention Grant
- Patent Title: Cyanopyrrolidines as dub inhibitors for the treatment of cancer
-
Application No.: US15738900Application Date: 2016-07-14
-
Publication No.: US10669234B2Publication Date: 2020-06-02
- Inventor: Mark Kemp , Martin Stockley , Alison Jones
- Applicant: MISSION THERAPEUTICS LIMITED
- Applicant Address: GB Cambridge
- Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee: MISSION THERAPEUTICS LIMITED
- Current Assignee Address: GB Cambridge
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@85673a7 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@d8b61e1
- International Application: PCT/GB2016/052130 WO 20160714
- International Announcement: WO2017/009650 WO 20170119
- Main IPC: C07D207/16
- IPC: C07D207/16 ; C07D413/14 ; C07D403/06 ; C07D403/14 ; C07D413/06 ; C07D417/12 ; C07D417/14 ; C07D471/04 ; C07D401/06 ; C07D401/14 ; A61P25/28 ; A61P35/00 ; C07D209/04

Abstract:
The present invention relates to novel compounds and method for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1) and ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of cancer and conditions involving mitochondrial dysfunction. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined herein.
Public/Granted literature
- US20180194724A1 CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER Public/Granted day:2018-07-12
Information query